Last update 01 Nov 2024

GlaxoSmithKline KK

Subsidiary Company|
1928|
Tokyo-to, Japan
|
www.glaxosmithkline.co.jp

Overview

Tags

Infectious Diseases
Respiratory Diseases
Other Diseases
Small molecule drug
Prophylactic vaccine
Genetically engineered subunit vaccine

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Infectious Diseases16
Immune System Diseases10
Hemic and Lymphatic Diseases6
Neoplasms4
Nervous System Diseases2
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Small molecule drug20
Prophylactic vaccine4
Monoclonal antibody2
Genetically engineered subunit vaccine2
Top 5 TargetCount
GR(Glucocorticoid receptor)2
Microtubule-associated proteins1
mAChRs(Muscarinic acetylcholine receptor)1
PGI2 receptor(Prostanoid IP receptor)1
HIF-PHs(Hypoxia-inducible factor prolyl hydroxylase)1

Related

26
Drugs associated with GlaxoSmithKline KK
Momelotinib Dihydrochloride
Target
ALK2 x JAK1 x JAK2
Mechanism
ALK2 inhibitors [+2]
Active Org.
GSK PlcGSK Plc [+4]
Originator Org.
Gilead Sciences, Inc.Gilead Sciences, Inc.
Active Indication
Anemia [+8]
Inactive Indication
EGFR-mutated non-small Cell Lung Cancer [+6]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date15 Sep 2023
Respiratory Syncytial Virus Vaccine (GSK)
Target-
Mechanism
Immunostimulants
Active Org.
GlaxoSmithKline, Inc. [+4]
Originator Org.
GSK PlcGSK Plc
Active Indication
Respiratory Syncytial Virus Infections [+1]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date03 May 2023
Pirtobrutinib
Target
BTK C481S
Mechanism
BTK C481S inhibitors
Active Org.
Loxo Oncology, Inc.Loxo Oncology, Inc. [+8]
Originator Org.
Redx Pharma PlcRedx Pharma Plc
Active Indication
Mantle-Cell Lymphoma [+11]
Inactive Indication
Liver Injury [+1]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date27 Jan 2023
37
Clinical Trials associated with GlaxoSmithKline KK
JPRN-jRCT1061230097 / RecruitingNot ApplicableIIT
A study to verify the acute therapeutic effect of mepolizumab for eosinophilicpolyangiitis granulomatosis (EGPA) neuropathy(A Prospective Observational Study)
JPRN-jRCT1080224526 / CompletedNot Applicable
Generation and Cognitive Testing of Informative and Suitable Items for a COPD Exacerbation Recognition Tool (CERT) for Detection of Exacerbations of COPD in Japanese Patients
JPRN-JapicCTI-194593 / CompletedNot Applicable
Generation and Cognitive Testing of Informative and Suitable Items for a COPD Exacerbation Recognition Tool (CERT) for Detection of Exacerbations of COPD in Japanese Patients
100 Clinical Results associated with GlaxoSmithKline KK
Login to view more data
0 Patents (Medical) associated with GlaxoSmithKline KK
Login to view more data
100 Deals associated with GlaxoSmithKline KK
Login to view more data
100 Translational Medicine associated with GlaxoSmithKline KK
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
26
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free